Your browser doesn't support javascript.
loading
Truncating NFKB1 variants cause combined NLRP3 inflammasome activation and type I interferon signaling and predispose to necrotizing fasciitis.
Nurmi, Katariina; Silventoinen, Kristiina; Keskitalo, Salla; Rajamäki, Kristiina; Kouri, Vesa-Petteri; Kinnunen, Matias; Jalil, Sami; Maldonado, Rocio; Wartiovaara, Kirmo; Nievas, Elma Inés; Denita-Juárez, Silvina Paola; Duncan, Christopher J A; Kuismin, Outi; Saarela, Janna; Romo, Inka; Martelius, Timi; Parantainen, Jukka; Beklen, Arzu; Bilicka, Marcelina; Matikainen, Sampsa; Nordström, Dan C; Kaustio, Meri; Wartiovaara-Kautto, Ulla; Kilpivaara, Outi; Klein, Christoph; Hauck, Fabian; Jahkola, Tiina; Hautala, Timo; Varjosalo, Markku; Barreto, Goncalo; Seppänen, Mikko R J; Eklund, Kari K.
Afiliación
  • Nurmi K; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland.
  • Silventoinen K; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland.
  • Keskitalo S; Systems Biology/Pathology Research Group, iCAN Digital Precision Cancer Medicine Flagship, Institute of Biotechnology, HiLIFE, UH, 00014 Helsinki, Finland.
  • Rajamäki K; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland; Department of Medical and Clinical Genetics, Applied Tumor Genomics Research Program, RPU, UH, 00014 Helsinki, Finland.
  • Kouri VP; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland.
  • Kinnunen M; Systems Biology/Pathology Research Group, iCAN Digital Precision Cancer Medicine Flagship, Institute of Biotechnology, HiLIFE, UH, 00014 Helsinki, Finland.
  • Jalil S; Clinical Genetics UH and Helsinki University Hospital (HUH), 00014 Helsinki, Finland.
  • Maldonado R; Clinical Genetics UH and Helsinki University Hospital (HUH), 00014 Helsinki, Finland.
  • Wartiovaara K; Clinical Genetics UH and Helsinki University Hospital (HUH), 00014 Helsinki, Finland.
  • Nievas EI; Alexander Fleming Hospital, OSEP, CP 5501 Mendoza, Argentina.
  • Denita-Juárez SP; HEMA, Laboratory for Clinical Genetics, CP 5501 Mendoza, Argentina.
  • Duncan CJA; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 4HH, UK.
  • Kuismin O; Department of Clinical Genetics, Oulu University Hospital (OUH), 90014 Oulu, Finland; PEDEGO Research Unit and Medical Research Center Oulu, OUH and University of Oulu (OU), 90014 Oulu, Finland.
  • Saarela J; Institute for Molecular Medicine Finland, HiLIFE, UH, 00014 Helsinki, Finland; Centre for Molecular Medicine Norway, University of Oslo, 0313 Oslo, Norway; Department of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.
  • Romo I; Inflammation Center, Department of Infectious Disease, HUH, 00029 Helsinki, Finland.
  • Martelius T; Inflammation Center, Department of Infectious Disease, HUH, 00029 Helsinki, Finland.
  • Parantainen J; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland.
  • Beklen A; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland.
  • Bilicka M; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland.
  • Matikainen S; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland.
  • Nordström DC; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland; Department of Internal Medicine and Rehabilitation, HUH and UH, 00029 Helsinki, Finland.
  • Kaustio M; Institute for Molecular Medicine Finland, HiLIFE, UH, 00014 Helsinki, Finland.
  • Wartiovaara-Kautto U; Department of Hematology, HUH, Comprehensive Cancer Center, UH, 00029 Helsinki, Finland; Applied Tumor Genomics Research Program, RPU, Faculty of Medicine, UH, 00014 Helsinki, Finland.
  • Kilpivaara O; Applied Tumor Genomics Research Program, RPU, Faculty of Medicine, UH, 00014 Helsinki, Finland; Department of Medical and Clinical Genetics/Medicum, Faculty of Medicine, UH, 00014 Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, UH, 00014 Helsinki, Finland; HUS Diagnostic Center,
  • Klein C; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, 80337 Munich, Germany.
  • Hauck F; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, 80337 Munich, Germany.
  • Jahkola T; Department of Plastic Surgery, HUH, 00029 Helsinki, Finland.
  • Hautala T; Research Unit of Internal Medicine and Biomedicine, OU, and Infectious Diseases Clinic, OUH, 90014 Oulu, Finland.
  • Varjosalo M; Systems Biology/Pathology Research Group, iCAN Digital Precision Cancer Medicine Flagship, Institute of Biotechnology, HiLIFE, UH, 00014 Helsinki, Finland.
  • Barreto G; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland.
  • Seppänen MRJ; Adult Immunodeficiency Unit, Infectious Diseases, Inflammation Center, HUH and UH, 00029 Helsinki, Finland; Rare Disease Center, Children and Adolescents, HUH and UH, 00029 Helsinki, Finland. Electronic address: mikko.seppanen@hus.fi.
  • Eklund KK; Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland; Department of Rheumatology, HUH and UH, 00029 Helsinki, Finland; Orton Orthopaedic Hospital, 00280 Helsinki, Finland. Electronic address: kari.
Cell Rep Med ; 5(4): 101503, 2024 Apr 16.
Article en En | MEDLINE | ID: mdl-38593810
ABSTRACT
In monogenic autoinflammatory diseases, mutations in genes regulating innate immune responses often lead to uncontrolled activation of inflammasome pathways or the type I interferon (IFN-I) response. We describe a mechanism of autoinflammation potentially predisposing patients to life-threatening necrotizing soft tissue inflammation. Six unrelated families are identified in which affected members present with necrotizing fasciitis or severe soft tissue inflammations. Exome sequencing reveals truncating monoallelic loss-of-function variants of nuclear factor κ light-chain enhancer of activated B cells (NFKB1) in affected patients. In patients' macrophages and in NFKB1-variant-bearing THP-1 cells, activation increases both interleukin (IL)-1ß secretion and IFN-I signaling. Truncation of NF-κB1 impairs autophagy, accompanied by the accumulation of reactive oxygen species and reduced degradation of inflammasome receptor nucleotide-binding oligomerization domain, leucine-rich repeat-containing protein 3 (NLRP3), and Toll/IL-1 receptor domain-containing adaptor protein inducing IFN-ß (TRIF), thus leading to combined excessive inflammasome and IFN-I activity. Many of the patients respond to anti-inflammatory treatment, and targeting IL-1ß and/or IFN-I signaling could represent a therapeutic approach for these patients.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Interferón Tipo I / Fascitis Necrotizante Idioma: En Revista: Cell Rep Med Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Interferón Tipo I / Fascitis Necrotizante Idioma: En Revista: Cell Rep Med Año: 2024 Tipo del documento: Article